We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
-20.33%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.3B
AUM Growth
-$379M
Cap. Flow
+$105M
Cap. Flow %
8.09%
Top 10 Hldgs %
48.93%
Holding
86
New
8
Increased
9
Reduced
24
Closed
9

Top Buys

Rank Stock Value
1
GRNA
GreenLight Biosciences Holdings, PBC Common Stock
GRNA
+$60.1M
2
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$28.4M
3
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$22.7M
4
APLS
Apellis Pharmaceuticals
APLS
+$22.1M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$16.9M

Top Sells

Rank Stock Value
1
BEAM icon
Beam Therapeutics
BEAM
+$26.9M
2
ACRS icon
Aclaris Therapeutics
ACRS
+$13.1M
3
VERV
Verve Therapeutics
VERV
+$11.7M
4
CYTK icon
Cytokinetics
CYTK
+$10.7M
5
ZYME icon
Zymeworks
ZYME
+$9.83M

Sector Composition

Rank Sector Weight
1 Healthcare 98.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTK icon
26
Cytokinetics
CYTK
$10.4B
$14.7M 1.13%
400,000
-300,000
-43% -$10.7M
BMEA icon
27
Biomea Fusion
BMEA
$91.3M
$14.1M 1.09%
3,170,872
– –
RCKT icon
28
Rocket Pharmaceuticals
RCKT
$394M
$13.8M 1.06%
868,550
– –
PHVS icon
29
Pharvaris
PHVS
$2.44B
$12.4M 0.95%
684,888
-4,843
-0.7% -$85.4K
LBPH
30
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$12.1M 0.93%
2,273,221
– –
ALXO icon
31
ALX Oncology
ALXO
$290M
$12M 0.92%
712,079
-50,000
-7% -$854K
RAIN
32
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$11.8M 0.91%
2,326,660
– –
TRML
33
DELISTED
Tourmaline Bio
TRML
$11.6M 0.89%
117,472
-783
-0.7% -$73.3K
AVIR icon
34
Atea Pharmaceuticals
AVIR
$420M
$11.2M 0.86%
1,547,181
-132,261
-8% -$898K
GHRS icon
35
GH Research
GHRS
$2.08B
$11.1M 0.85%
608,123
– –
IGMS
36
DELISTED
IGM Biosciences
IGMS
$10.8M 0.83%
402,200
-97,800
-20% -$1.82M
VTYX
37
DELISTED
Ventyx Biosciences
VTYX
$10.7M 0.82%
785,303
– –
HZNP
38
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$10.5M 0.81%
+100,000
New +$9.75M
AMAM
39
DELISTED
Ambrx Biopharma Inc
AMAM
$10.2M 0.79%
2,486,386
– –
BCAB icon
40
BioAtla
BCAB
$5.74M
$10.2M 0.78%
40,764
+7,142
+21% +$2.99M
VECT
41
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$9.79M 0.75%
2,078,485
-138,278
-6% -$723K
BHVN
42
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$9.49M 0.73%
+80,000
New +$9.98M
ITCI
43
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$9.18M 0.7%
+150,000
New +$7.79M
OLMA icon
44
Olema Pharmaceuticals
OLMA
$1.05B
$8.87M 0.68%
2,082,000
-87,871
-4% -$484K
TYRA icon
45
Tyra Biosciences
TYRA
$1.58B
$8.11M 0.62%
757,432
-82,500
-10% -$979K
PRAX icon
46
Praxis Precision Medicines
PRAX
$10.1B
$7.68M 0.59%
50,160
– –
ASND icon
47
Ascendis Pharma A/S
ASND
$16.8B
$5.87M 0.45%
50,000
– –
AKRO
48
DELISTED
Akero Therapeutics
AKRO
$5.73M 0.44%
403,787
– –
KROS icon
49
Keros Therapeutics
KROS
$221M
$5.44M 0.42%
100,000
-50,000
-33% -$2.57M
BEAM icon
50
Beam Therapeutics
BEAM
$2.84B
$5.16M 0.4%
90,045
-409,955
-82% -$26.9M
1
2
3 4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q1 2022 Portfolio in Review

As of Q1 2022, Cormorant Asset Management held 86 positions worth $1.3B, down 23% from $1.68B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Cormorant Asset Management deployed $105M of net new capital in Q1 2022, opening 8 new positions and adding to 9 existing holdings. Its largest new stake was GreenLight Biosciences Holdings, PBC Common Stock: 6,710,540 shares worth $62M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier.

On the sell side, the largest reduction was Beam Therapeutics, an estimated $26.9M trimmed.

  • Cormorant Asset Management's largest Q1 2022 buy was GreenLight Biosciences Holdings, PBC Common Stock: 6,710,540 shares worth $62M.
  • Cormorant Asset Management added most to MoonLake Immunotherapeutics in Q1 2022, an estimated $28.4M increase.
  • Cormorant Asset Management's biggest Q1 2022 reduction was Beam Therapeutics, cutting an estimated $26.9M.
  • Cormorant Asset Management fully exited Aclaris Therapeutics in Q1 2022, selling an estimated $13.1M.
  • Cormorant Asset Management's ten largest holdings make up 49% of its $1.3B portfolio in Q1 2022.
  • Cormorant Asset Management opened 8 new positions and closed 9 in Q1 2022.
  • Cormorant Asset Management's portfolio value fell 23% quarter-over-quarter to $1.3B.

Based on Cormorant Asset Management's 13F filing for Q1 2022, filed 16 May 2022.